Eczema Clinical Trial
Enrolling Now

Clinics: Greater Manchester

Therapy Area: Atopic Dermatitis

Gender and Age: Males & Females aged 18 – 59

Reimbursement: Up to £2930 plus reasonable travel expenses

About The Research...

MAC Clinical Research is currently conducting a clinical trial to test an investigational drug for eczema, also known as atopic dermatitis. Eczema is one of the most common types of skin diseases and affects up to 10% of adults. Common features of this inflammatory skin disease include itching and dryness. Eczema often relapses, meaning symptoms will improve for a while but then return.

What causes eczema is not yet known, however high levels of a protein called interleukin 22 (IL-22) in the body are believed to play a role in the disease.

The trial drug aims to reduce the symptoms of eczema by decreasing the activity levels of IL-22 in the body. If the trial drug is proven to work, it could be used to treat people with moderate to severe eczema in the future.

The purpose of this trial is to test if the trial drug is safe and improves eczema by looking at any changes in your skin, and to see how well tolerated it is. During the trial, eligible participants will receive the trial drug or placebo (a substance used as a ‘dummy medication’ which has no active ingredient or drug in it).

The study will last approx. 23 weeks and over that time there will be:
11 x outpatient visits (some may be remote)
1 x in-patient stay of up to 2 nights
4 x in-patient stays of 1 night

If you are eligible and you decide to take part, you may be helping the development of a new potential treatment that may help improve the quality of life for many people with eczema.

A full description of the study will be given before you decide to take part, both over the phone and during an appointment at a MAC clinic. This will include you receiving the full patient information sheet (PIS).

Reimbursement: Up to £2930 plus reasonable travel expenses


* Key Inclusion Criteria:

  • Male or female 18 to 59
  • Diagnosis of eczema for at least the past 6 months
  • BMI 18 – 32 kg/m2

* Key Exclusion Criteria:

  • History of tanning beds or phototherapy within 6 weeks of starting trial
  • History of any severe allergic reactions
  • Active skin conditions other than eczema

Other eligibility criteria will apply. Please contact MAC for more information.

Eligible patients will receive a comprehensive health screen and study participation will be in collaboration with the patient’s treating physician.

MAC Clinical Research is conducting a trial to evaluate a potential new treatment for eczema.

If you would like more information, please fill in the form below and we will be in touch…

Alternatively, please call our recruitment team on freephone 0800 633 5507.

  • (You can enter any supporting information here)
Data Privacy Statement

Know someone who may be interested in taking part? Share this page here:

Share on facebook
Share on twitter
Share on whatsapp
Share on email